摘要
目的探讨原发性肝癌(PLC)患者经肝癌切除术联合经导管动脉内化疗栓塞(TACE)后细胞免疫及调节性T淋巴细胞的变化及其临床价值。方法采用流式细胞术检测健康者及PLC患者肝癌切除术联合3次TACE治疗后外周血CD3、CD3+CD4+、CD3+CD8+T细胞及调节性T淋巴细胞,同时采用化学发光法监测血清甲胎蛋白(AFP)的变化。结果 PLC患者肝癌切除术联合3次TACE治疗外周血中CD3+、CD3+CD4+、CD3+CD8+T细胞数均显著低于健康对照组(P<0.05),但3个治疗组组间差异无显著性(P>0.05);3个治疗组患者CD4+CD25+FoxP3+T细胞的比例均高于健康对照组(P<0.05),但3个治疗组组间差异无显著性(P>0.05);AFP阳性患者TACE治疗期间,AFP的水平均远远高于健康者(P<0.05),三个治疗组间差异无统计学意义(P>0.05);CD4+CD25+FoxP3+T细胞与血清AFP的相关系数为0.542。结论 TACE并不能改善PLC患者肝癌切除术后的免疫状况,但机体的细胞免疫与疾病的发展呈正相关的。
Objective To investigate the changes of cellular immune function and regulatory T cells of patients with primary liver cancer（PLC） who had accepted liver resection combined with transcatheter arterial chemoembolization（TACE） and its clinical value. Methods Flow eytometry was employed to detect peripheral blood CD3^＋ ,CD3^＋ CD4^＋ ,CD3^＋ CD8^＋ T cells of healthy people and PLC patients who had accepted liver resection combined with three times TACE. Chemiluminescence was used to monitor the serum alpha-fetoprotein（AFP） changes. Results The numbers of peripheral blood CD3,CD3^＋ CD4^＋ ,CD3^＋ CD8^＋ T cells of PLC patients were significantly lower than those in health control group（P〈0.05）, with no statistical differences among three treatment groups（P〈0.05）. The CD4^＋ CD25^＋ FoxP3^＋ T cellst ratios of patients in the three groups were all higher than those in health control group（P〈0.05）,with no statistical differences among three treatment groups（P〈0. 05）. AFP level of patients with positive AFP during TACE treatment was markedly higher than that in healthy people（P〈0.05）, with no statistical differences among three treatment groups（P〉0.05）. Correlation coefficient of CD4^＋ CD25^＋ FoxP3^＋ T cells and serum AFP was 0. 542. Conclusion TACE treatment could not improve the immune status of PLC patients after hepatectomy, but the body＇s cellular immunity shows positive correlation with disease development.
出处
《国际检验医学杂志》
CAS
2013年第21期2825-2826,2829,共3页
International Journal of Laboratory Medicine
基金
新疆自治区卫生厅青年科技人才专项基金项目(2008Y06)
